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Abstract The novel chemical structure and immunobiological
activities of Prevotella intermedia ATCC 25611 lipid A were
investigated. A lipopolysaccharide (LPS) preparation of P. in-
termedia was extracted using a phenol^chloroform^petroleum
ether method, after which its puri¢ed lipid A was prepared by
weak acid hydrolysis followed by chromatographic separations.
The lipid A structure was determined by mass spectrometry and
nuclear magnetic resonance to be a diglucosamine backbone
with a phosphate at the 4-position of the non-reducing side
sugar, as well as ¢ve fatty acids containing branched long
chains. It was similar to that of Bacteroides fragilis and Por-
phyromonas gingivalis, except for the phosphorylation site.
P. intermedia lipid A induced weaker cytokine production and
NF-UB activation in murine cells via Toll-like receptor (TLR)
4 as compared to Escherichia coli synthetic lipid A (compound
506). Our results indicate that P. intermedia lipid A activates
cells through a TLR4-dependent pathway similar to E. coli-type
lipid A, even though these have structural di¡erences.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Lipopolysaccharide (LPS) is an outer membrane compo-
nent of Gram-negative bacteria, and exhibits powerful immu-
nostimulatory and in£ammatory activities. It is composed of a
heterogeneous mixture of large molecular weight compounds
composed of a polysaccharide part, O-antigen and core re-
gions, and a lipid anchor called lipid A. Among these, lipid
A moiety is known to be essential for the activity of LPS [1].
Recently, it has been shown that lipid A of Escherichia coli
and its related species induces mammalian cell activation via
an innate immunity receptor, Toll-like receptor (TLR) 4, and
its accessory protein MD-2 complex [2]. On the other hand,
LPS and lipid A preparations from Bacteroides fragilis and
Porphyromonas gingivalis have been proposed to induce cell
activation independently from TLR4 through TLR2-mediated
signal transduction [3^6]. These di¡erent results have been
shown to be responsible for the structural di¡erences of lipid
A moiety in LPS [7]. Lipid A from E. coli consists of a diglu-
cosamine (GlcN2) backbone carrying two phosphates at the
1-position of the reducing side and the 4-position of the non-
reducing side of GlcN, which is a hexaacyl substituent. In
contrast, B. fragilis and P. gingivalis lipid As are composed
of the same backbone with a phosphate at the 1-position of
the reducing side GlcN, and three to ¢ve branched long-chain
fatty acids [8^10].
To con¢rm the activities of P. gingivalis lipid A, we recently
prepared a highly puri¢ed version of its natural lipid A and a
synthetic counterpart, and then examined their immunobio-
logical activities [11,12]. P. gingivalis natural and synthetic
lipid As, similar to E. coli-type lipid A, activated cells through
a TLR4^MD-2-dependent pathway, but not via TLR2. These
results suggest that the lipid A itself is recognized by the
TLR4^MD-2 complex, regardless of its molecular structure,
while the previous observation seems to have been a¡ected by
some contaminants, which activated cells in a TLR2-depen-
dent manner in conventional-grade natural lipid A.
Prevotella intermedia, a Gram-negative black-pigmented
bacterium, is dominant in the periodontal pockets of patients
with gingivitis and has been implicated as a pathogen in pe-
riodontal diseases [13]. P. intermedia LPS has been reported to
activate cells through a TLR4-independent pathway [4]. No
information regarding the chemical structure of lipid A from
P. intermedia or its immunobiological activity is available;
therefore, we considered it necessary to determine whether
our observation is suitable for P. intermedia lipid A. In this
study, we elucidated the chemical structure of lipid A from
P. intermedia and examined its immunobiological activities.
2. Materials and methods
2.1. Bacteria, LPS, and lipid A
P. intermedia ATCC 25611 organisms were grown anaerobically in
Gifu anaerobic medium broth (Nissui, Tokyo, Japan) at 37‡C for 24 h.
Bacterial cells were collected by centrifugation, then washed three
times with saline and lyophilized. LPS preparations were extracted
from the lyophilized cells using a phenol^chloroform^petroleum ether
method [14] and lipid A was prepared from the LPS preparations
according to our method described previously [12]. Brie£y, hydropho-
bic products obtained by weak acid hydrolysis of the LPS preparation
were subjected to silica gel column chromatography to yield a lipid A
fraction. The fraction was further subjected to two successive prepa-
rative silica gel thin-layer chromatography TLC) runs, using a solvent
system consisting of chloroform^methanol^water (65/25/4, v/v/v) fol-
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lowed by a chloroform^methanol^ammonia solution (65/25/5, v/v/v)
to yield the puri¢ed lipid A. E. coli-type lipid A (compound 506) was
chemically synthesized as described previously [12,15].
2.2. Analytical procedures
Sugar constituents were analyzed using the alditol acetate method
[16]. The absolute con¢gurations of sugar were determined using
R-(+)-2-butanol [17], while fatty acids were analyzed according to
the method of Ikemoto et al. [18]. Sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) was performed using 15%
polyacrylamide gels according to the method of Laemmli [19]. The
gel was partially oxidized with periodic acid and then visualized by the
silver staining method [20]. Analytical TLC was performed on a TLC
plate (No. 5715; Merck, Darmstadt, Germany) using a solvent system
consisting of chloroform^methanol^water (65/25/4, v/v/v) and the
spots were visualized with anisaldehyde-sulfuric acid reagent.
2.3. Nuclear magnetic resonance (NMR) spectroscopy and mass
spectrometry (MS)
1H, 13C, and 31P NMR spectra were measured at 500, 126, and 202
MHz, respectively, on a JMN-LA500 spectrometer (JEOL, Tokyo,
Japan) equipped with an indirect detection gradient probe, IDG500-
5VJ (Nanorac Cryogenics, Martinez, CA, USA). Spectra of lipid A
were obtained at 303 or 310 K at a concentration of 2 mg ml31 in
CDCl3^CD3OD (4/1, v/v). The chemical shifts are expressed in
N values using chloroform (N=7.26) as an internal standard for 1H
NMR spectra, methanol (N=49.0) as an internal standard for 13C
NMR spectra. For 31P NMR spectra, a capillary insert containing
85% phosphoric acid was used as an external standard (N=0). The
signals were assigned using DQF-COSY, NOESY, and 1H^13C het-
eronuclear multiple bond connectivity (HMBC) spectra. The coupling
constants were determined by one-dimensional 1H NMR in combina-
tion with DQF-COSY.
Matrix-assisted laser desorption/ionization time-of-£ight (MALDI-
TOF)-MS spectra were measured using an Ultra£ex (Bruker Daltnics,
Bremen, Germany) instrument. Samples were dissolved in chloro-
form^methanol (4/1, v/v) combined with 2,5-dihydroxybenzoic acid
as a matrix, and then placed on a sample plate. Spectra were obtained
in negative and positive ion re£ector modes. Tandem MS (MS/MS)
spectra were obtained in positive ion TOF/TOF mode.
2.4. Cytokine assays
C3H/HeN and C3H/HeJ mice were peritoneally injected with sterile
Brewer’s thioglycolate broth (Becton Dickinson, Franklin Lakes, NJ,
USA). After 3 days, the peritoneal cavity of each animal was washed
twice with phosphate-bu¡ered saline (PBS; Sigma, St. Louis, MO,
USA) and the cell suspensions thus obtained were washed three times
with PBS by centrifugation. The peritoneal exudate cells were then
suspended in RPMI1640 (Sigma) supplemented with 10% fetal bovine
serum (FBS; Sigma) at 2U105 cells/200 Wl and distributed in each well
of a 96-well microculture plate (Falcon 3072, Becton Dickinson), after
which they were incubated for 2 h at 37‡C in humidi¢ed air contain-
ing 5% CO2. Each well was washed twice with PBS to remove non-
adherent cells and cells attached to the culture plate served as perito-
neal macrophages. The cells were incubated with the indicated doses
of the test specimens for 24 h at 37‡C in humidi¢ed air containing 5%
CO2. Interleukin 6 (IL-6) production was measured in the culture
supernatants using a commercial ELISA kit system (eBioscience,
San Diego, CA, USA) according to the manufacturer’s instructions.
The results were determined using a standard curve prepared for each
assay.
2.5. Luciferase assays
Ba/F3 cells stably expressing p55IgULuc, an NF-UB-dependent lu-
ciferase reporter construct (Ba/UB), murine TLR2 and the p55IgULuc
reporter construct (Ba/mTLR2), and murine TLR4/MD-2 and the
p55IgULuc reporter construct (Ba/mTLR4/mMD-2), were kindly pro-
vided by Dr. K. Miyake (Division of Infectious Genetics, Department
of Microbiology and Immunology, Institute of Medical Science, Uni-
versity of Tokyo, Japan), and maintained as described previously [12].
The cells were inoculated onto 96-well £at-bottomed microtiter plates
at 1U105 cells/well in 100 Wl of RPMI1640 supplemented with 10%
FBS, and stimulated with the indicated doses of the test specimens.
After 4 h at 37‡C, 100 Wl of Bright-Glo1 luciferase assay reagent
(Promega, Madison, WI, USA) was added to each well and lumines-
cence was quanti¢ed with a luminometer (Turner Designs Luminom-
eter Model TD-20/20; Promega). Results are shown as relative lucif-
erase activity, which is the ratio of stimulated to non-stimulated
activity in each cell line.
2.6. Statistical analysis
Data were analyzed by one-way ANOVA (analysis of variance),
using the Bonferroni or Dunn method, and the results are presented
as the meanTS.E.M. When an individual result is presented, it is
representative of at least three independent experiments.
3. Results and discussion
3.1. Isolation of lipid A from P. intermedia
Since LPS from P. intermedia ATCC 25611 was reported to
be the rough form [21], the bacteria were subjected to PCP
extraction [14] to obtain LPS preparations with a yield of
0.85%. An SDS^PAGE pro¢le of the preparations proved
them to be the rough form (data not shown). The prepara-
tions were subjected to weak acid hydrolysis to give hydro-
Table 1
Proton NMR data for P. intermedia lipid A
Residues Chemical shifts (coupling constants)
H1 (3J1;2) H2 (3J2;3) H3 (3J3;4) H4 (3J4;5) H5 H6a H6b
Sugars
Major signals
GlcNI 4.89 (3.6) 3.88 (10.7) 4.97 (9.2) 3.27 (9.6) 3.85 3.55 3.85
GlcNII 4.40 (8.3) 3.68 (10.4) 5.00 (9.2) 4.05 3.23 3.60 3.72
Minor signals
GlcNI 4.47 (8.6) 3.60 (10.6) 4.78 (8.6) 3.29 3.56 3.87 nd
GlcNII 4.39 nd nd nd nd nd
Fatty acids
A ^ 2.02 3.66 1.12
2.12 1.27
B ^ 2.18 3.78 1.25
2.28 1.30
C ^ 2.26 3.85 1.23
1.30
D ^ 2.14 4.90 1.36
2.27
E ^ 2.10 1.39
Spectra were measured at 303 K. Chemical shifts are expressed as N values and coupling constants are shown in parentheses.
nd: not determined.
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phobic products. In the TLC analysis, one major (Rf = 0.5)
and several minor spots were detected in the hydrophobic
products. The major component was isolated by silica gel
chromatography followed by two successive preparative
TLC separations as described previously [12]. The yield of
the component was 7%, based on the LPS preparation. This
component was used as puri¢ed lipid A.
3.2. Structural elucidation of lipid A
The molecular mass of lipid A was measured by MALDI-
TOF-MS in the negative ion mode. Ion peaks were observed
at m/z 1688.4, 1702.4, and 1716.4 in a relative intensity ratio
of 0.6:1.0:0.7, indicating lipid A structures that corresponded
to the GlcN2 backbone with a phosphate, four hydroxy fatty
acids, and a non-hydroxy fatty acid. Fatty-acid analysis re-
vealed that the component mainly contained 15-Me-16:0 (3-
OH), 16:0 (3-OH), 12-Me-14:0, and 12-Me 13:0 in a molar
ratio of 3.1:1.1:1.5:1.0, thus, the heterogeneity of the molec-
ular weight was explained by the substitution of di¡erent
combinations of fatty acids, e.g. m/z 1702.4 was considered
to contain 13-Me-14:0, 16:0 (3-OH), 15-Me-16:0 (3-OH) in a
molar ratio of 1:1:3.
The detailed structure of lipid A was established by NMR.
The 1H NMR of the puri¢ed lipid A was assigned using
DQF-COSY, NOESY, and 1H^13C HMBC, and the data
are summarized in Table 1. Two sets of sugar signals were
mainly observed. The coupling constants and NOESY corre-
lation (Fig. 1a) of the signals revealed a glucopyranosyl con-
Fig. 1. NOESY spectra (a), 1H^31P HMBC spectra (b), and 1H-13C
HMBC spectra (c) of P. intermedia lipid A. Spectra were measured
at 303 K for panels a and c, and 310K for panel b.
   
   
    
   
  
   
Fig. 2. a: MS/MS spectrum of the parent ion at m/z 1726.2. b: A
proposed chemical structure of P. intermedia lipid A.
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¢guration of the sugar. Since only D-GlcN was seen in the
compositional analysis, the sugars were determined to be
GlcN, and designated as GlcNI and GlcNII in order of the
1H chemical shift of the anomeric proton. The coupling con-
stant (3.6 Hz) for the anomeric proton of GlcNI (H1I) at
N=4.89 showed an K con¢guration. The H1I signal did not
shift to a lower ¢eld, con¢rming no phosphorylation at the
anomeric position, i.e. GlcNI had a free anomeric hydroxy
group. The coupling constant (8.3 Hz) for the anomeric pro-
ton of GlcNII (H1II) at N=4.40 showed a L con¢guration and
interresidual NOESY coupling from H1II to H6I proved gly-
cosylation at the 6-position of GlcNI (Fig. 1a). Therefore,
GlcNI was categorized as a reducing side sugar and GlcNII
as a non-reducing one. The down¢eld shift of the signal for
H4II (N=4.05) revealed a phosphate substitution at the 4-po-
sition of GlcNII. Although the coupling constant for JH; P
could not be determined at the H4II signal due to line broad-
ening, the long-range HMBC coupling between H4II and the
phosphate (N=1.75) proved phosphorylation (Fig. 1b). H3I
and H3II signals appeared at N=4.97 and N=5.00, respec-
tively, and the down¢eld shift of the signals displayed the
acyl substitution at each 3-position. 1H^13C HMBC and
MS/MS spectra further revealed the acylation patterns. Cou-
plings between H3I and the carbonyl carbon of fatty acid A
(C1FAA), and H3II and C1FAB were observed in the HMBC
spectra, showing acylations of FA-A at the 3-position of
GlcNI and FA-B at the 3-position of GlcNII (Fig. 1c). Cou-
pling between H3FAD and C1FAE displayed that FA-E was
attached at the 3-position of FA-D. The positions of FA-C
and -D substitution were determined from positive ion MS/
MS spectra (Fig. 2a). The fragmentation pattern of the parent
ion at m/z 1726.2 [M+Na]þ indicated that FA-D was linked at
the 2-position of GlcNII (Fig. 2b).
In the NMR spectra, several minor signals, which had less
than one-¢fth the intensity of major signals, were observed
and considered to be lipid A with a L anomeric con¢guration
of GlcNI. The existence of the opposite anomeric conformer
was attributable to the free anomeric hydroxy group of lipid
A. Thus, we proposed a structure for P. intermedia lipid A, as
shown in Fig. 2b.
Lipid A from closely related bacteria, B. fragilis NCTC
9343 [8], Bacteroides vulgatus IMCJ 1204 [22], P. gingivalis
381 [9], and P. gingivalis SU63 [10], have been reported to
possess fundamentally similar structures, e.g. a GlcN2 back-
bone attached to a phosphate at the 1-position of the reducing
side GlcN, and three to ¢ve branched long-chain fatty acids.
The present results show that P. intermedia lipid A has a
similar structure, including the acylation pattern and number
of phosphate groups, as the above-mentioned bacteria, except
for the phosphorylation position. Since some bacterial species
have been reported to have lipid A with a phosphorylation
only at the 4-position of the non-reducing side GlcN and no
substituent at the 1-position of the reducing one [23^25], the
lipid A in the present study was not an artifact created during
the preparation steps. However, its structural signi¢cance re-
mains unknown.
3.3. Immunobiological activity of lipid A
Cytokine production in peritoneal exudate macrophages
from LPS-responsive C3H/HeN and LPS-hyporesponsive
C3H/HeJ mice was investigated. P. intermedia lipid A induced
IL-6 production in peritoneal exudate macrophages from
C3H/HeN mice, whereas IL-6 production in those from
C3H/HeJ mice was negligible, similar to E. coli-type lipid A,
compound 506 (Fig. 3). Since C3H/HeJ mice have a dominant
negative point mutation in the cytoplasmic domain of TLR4
[26], these results indicate that cell activation by P. intermedia
lipid A is mediated by TLR4. Furthermore, the TLR4-medi-
ated signaling of P. intermedia was con¢rmed using murine
TLR-transfected Ba/F3 cells (Fig. 4). NF-UB activation by
P. intermedia lipid A, as well as by compound 506, was ob-
served in Ba/mTLR4/mMD-2, but not in Ba/mTLR2 or Ba/
UB cells, indicating that P. intermedia lipid A stimulates cells
via a TLR4-dependent pathway, but not by TLR2. These
¢ndings are consistent with the results of our previous study
of P. gingivalis [12], which found that its lipid A activated cells
through TLR4 in a similar manner as compound 506.
Although the signaling pathway of P. intermedia lipid A is
similar to E. coli-type lipid A, their activating intensity is quite
di¡erent. The activity of P. intermedia lipid A is more than
four orders weaker than compound 506 (Figs. 3 and 4). The
present results are also highly comparable with those for
P. gingivalis lipid A [12]. Furthermore, the weaker activities
of B. fragilis lipid A appear to be caused by di¡erences in
their chemical structure [27]. Compound 506 is composed of
GlcN2 backbone, six fatty acids and two phosphates, and
P. intermedia lipid A similar to P. gingivalis and B. fragilis
Fig. 3. IL-6 production in peritoneal exudate macrophages from
C3H/HeN and C3H/HeJ mice in response to stimulation by P. in-
termedia lipid A (a) and compound 506 (b). Data are expressed as
the meanTS.E.M. Signi¢cant di¡erences were seen between groups
with and without the test specimens (*P6 0.01).
Fig. 4. NF-UB activation in Ba/F3 cells in response to stimulation
by P. intermedia lipid A (a) and compound 506 (b). Data are shown
as relative luciferase activity.
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lipid A contains fewer fatty acids and phosphate as well as
longer fatty-acid chain lengths. Absence of a phosphate on
reducing or non-reducing GlcN of compound 506 reduced
endotoxic activities [28]. The activities of compound 406,
which lacks two of six fatty acids in compound 506, were
also reduced. A longer fatty-acid chain length may be respon-
sible for the reduction of activities [29]. Thus the weak activity
of P. intermedia lipid A is likely to be explained on the basis
of the structural di¡erences.
Taken together, these results clearly demonstrate the struc-
ture of lipid A from P. intermedia ATCC 25611 to be com-
posed of a GlcN2 backbone with ¢ve fatty acids and a phos-
phate. We also found that the lipid A activates murine cells
through a TLR4-mediated signaling pathway. Our ¢ndings
indicate that P. intermedia lipid A as well as that of E. coli
stimulate cell activation via TLR4, regardless of the substitu-
tion pattern of fatty acids and phosphate, or the kind of fatty
acids.
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